The FDA has granted fast track status to 67Cu-SAR-bisPSMA for metastatic prostate cancer that is resistant to hormone therapy ...

For patients with metastatic castration-resistant prostate cancer (mCRPC) unselected for homologous recombination repair (HRR ...

Real-world data support trial data on the use of lutetium-177 PSMA-617 in patients with PSMA-positive, metastatic castration-resistant prostate cancer.

For patients with metastatic castration-resistant prostate cancer (mCRPC) unselected for homologous recombination repair (HRR ...

Purchase price represents enterprise value of $85 million plus FibroGen net cash held in China at closing, currently estimated to be ...

Impact of baseline PSMA PET in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) starting first-line (1L) androgen receptor signaling inhibitor (ARSI) therapy. Barriers to ...

Genomic characteristics of patients with metastatic hormone-sensitive prostate cancer treated with ARPI-based therapy: A single-center analysis. Racial differences in organic anion transport proteins ...

FibroGen sells its China unit to AstraZeneca for $160 million, extending its cash runway into 2027 and advancing its ...

Reported encouraging early safety and efficacy data in ongoing dose escalation trial for ORIC-944 in combination with androgen receptor ...

Clarity Pharmaceuticals (ASX: CU6) ('Clarity' or 'Company'), a clinical-stage radiopharmaceutical company with a mission to develop next-generation products that improve treatment outcomes for ...

The deal involves an enterprise value of $85 million plus approximately $75 million in net cash held by FibroGen in China at the time of closing, totaling around $160 million. This strategic move will ...